Cyclo Therapeutics drug shows early positive results in NPC1 sub-study

Cyclo Therapeutics, through a collaboration with Rafael Holdings, reported preliminary findings from a Phase 3 sub-study of its investigational therapy Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick Disease Type C1 (NPC1). The open-label, single-arm trial assessed patients younger than three years old over 48 weeks. According to the company, of the nine patients who reached the 48-week […] The post Cyclo Therapeutics drug shows early positive results in NPC1 sub-study appeared first on Longevity.Technology.